Holen Sie sich die Stockscreener-App
23.67
2.19%
-0.53
Handel nachbörslich:
23.69
0.02
+0.08%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CAPR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$24.20
Offen:
$24
24-Stunden-Volumen:
785.28K
Relative Volume:
0.30
Marktkapitalisierung:
$1.29B
Einnahmen:
$27.10M
Nettoeinkommen (Verlust:
$-24.31M
KGV:
-28.52
EPS:
-0.83
Netto-Cashflow:
$-33.33M
1W Leistung:
+2.78%
1M Leistung:
-3.43%
6M Leistung:
+194.40%
1J Leistung:
+57.28%
1-Tages-Spanne:
$23.23
$24.48
1-Wochen-Bereich:
$23.23
$25.45
52-Wochen-Spanne:
$4.30
$40.37
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Firmenname
Capricor Therapeutics Inc
Sektor
Branche
Telefon
(310) 358-3200
Adresse
10865 ROAD TO THE CURE, SAN DIEGO, CA
Compare CAPR vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
23.67 | 1.32B | 27.10M | -24.31M | -33.33M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-30 | Eingeleitet | Alliance Global Partners | Buy |
| 2025-06-26 | Eingeleitet | B. Riley Securities | Buy |
| 2025-05-20 | Eingeleitet | Roth Capital | Buy |
| 2024-10-21 | Eingeleitet | Piper Sandler | Overweight |
| 2024-05-17 | Eingeleitet | Oppenheimer | Outperform |
| 2024-01-05 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-10-26 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2018-12-26 | Herabstufung | Maxim Group | Buy → Hold |
| 2018-01-26 | Bestätigt | H.C. Wainwright | Buy |
| 2017-09-15 | Bestätigt | H.C. Wainwright | Buy |
| 2017-02-13 | Fortgesetzt | Rodman & Renshaw | Buy |
| 2016-07-06 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-06-15 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Capricor Therapeutics Inc Aktie (CAPR) Neueste Nachrichten
Breakout Move: Whats the profit margin of Capricor Therapeutics Inc2025 Bull vs Bear & Weekly Momentum Stock Picks - baoquankhu1.vn
Following Sarepta Woes, Others Look To Unlock the Next Chapter in DMD Treatment - BioSpace
(CAPR) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Capricor Therapeutics (NASDAQ:CAPR) Shares Cross Above 50-Day Moving AverageTime to Sell? - MarketBeat
Capricor Therapeutics Stock Becomes Talk Of Retail Town On DMD Study; Retail Sees New Hope After Sarepta Setback - MSN
Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire
A Look At Capricor Therapeutics (CAPR) Valuation After Its New Shelf Registration Filing - Sahm
Phase III wins propel Capricor, Belite and DBV higher in December - BioWorld MedTech
TANG CAPITAL MANAGEMENT LLC Acquires Significant Stake in Capric - GuruFocus
Capricor Therapeutics, Inc. (CAPR): Uncovering the 124.68% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Oppenheimer reiterates Outperform rating on Capricor stock, maintains $54 target - Investing.com Canada
Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 6.7%Here's Why - MarketBeat
Does FDA’s No-New-Trial Stance on Deramiocel Shift the Bull Case for Capricor Therapeutics (CAPR)? - Sahm
Capricor Therapeutics (NASDAQ:CAPR) Shares Cross Above 50 Day Moving AverageShould You Sell? - MarketBeat
(CAPR) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
A Look At Capricor Therapeutics (CAPR) Valuation As FDA Advances Review Of Deramiocel BLA - Sahm
FDA Completes Inspection of Capricor Therapeutics Manufacturing Facility For Deramiocel Approval: Retail Sees ‘Unimaginable Potential’ - MSN
Highs Report: Whats the profit margin of Capricor Therapeutics IncBull Run & Weekly Stock Breakout Alerts - baoquankhu1.vn
Capricor Therapeutics, Inc. (CAPR): Investor Outlook On Promising 110% Upside Potential - DirectorsTalk Interviews
CAPR stock slides after FDA requests more data for genetic disorder therapy — what does retail think? - MSN
CAPR Updates FDA on Deramiocel BLA, Plans HOPE-3 CSR Filing in February - TradingView — Track All Markets
Does FDA’s HOPE-3 Data Request Clarify Deramiocel’s Regulatory Path For Capricor Therapeutics (CAPR)? - Sahm
Is FDA’s No-New-Trial Stance on Deramiocel Reshaping the Investment Case for Capricor Therapeutics (CAPR)? - Yahoo Finance
Is Capricor Therapeutics (CAPR) Still Attractive After A 72% One Year Share Price Jump - Yahoo Finance
Capricor Updates Deramiocel BLA Status After FDA Review of HOPE-3 Data - filmogaz.com
Capricor Therapeutics (CAPR) Valuation After FDA Requests HOPE-3 Data For Deramiocel Regulatory Review - Yahoo Finance
Capricor (CAPR) Plans February FDA Data Submission After 2% Stock Drop - Intellectia AI
CAPR Stock Slides After FDA Requests More Data For Genetic Disorder Therapy — What Does Retail Think? - Stocktwits
FDA Requests Capricor To Submit HOPE-3 Clinical Study Report For Deramiocel BLA Review - RTTNews
Capricor Therapeutics Provides Regulatory Updates Regarding Its Biologics License Application for Deramiocel - marketscreener.com
Capricor Therapeutics (CAPR) Moves Forward with Regulatory Update on Cell Therapy - GuruFocus
Capricor Therapeutics Inc. Provides Regulatory Update on Deramiocel BLA Submission Following FDA Request for HOPE-3 Clinical Study Report - Quiver Quantitative
FDA asks for full HOPE-3 data on DMD cell therapy, no new trials - Stock Titan
Capricor Therapeutics (NASDAQ:CAPR) Stock Passes Above 50 Day Moving AverageHere's Why - MarketBeat
‘Pharma Bro’ Martin Shkreli Calls His Capricor Therapeutics Short A 'Bad Call' After DMD Trial Delivers Surprise Win - MSN
Capricor Therapeutics stock rating reiterated by Cantor Fitzgerald - Investing.com UK
Cantor Fitzgerald reiterates Overweight rating on Capricor stock By Investing.com - Investing.com UK
A Look At Capricor Therapeutics (CAPR) Valuation After Deramiocel Phase 3 Success And Nippon Shinyaku Deals - Sahm
EV Market: Whats the profit margin of Capricor Therapeutics Inc2025 Major Catalysts & Smart Swing Trading Techniques - baoquankhu1.vn
Capricor Therapeutics (NASDAQ:CAPR) Cut to Sell at Wall Street Zen - MarketBeat
Why Capricor Therapeutics Inc. stock attracts high net worth investorsStock Surge & Risk Controlled Daily Plans - Улправда
Capricor Therapeutics: A High Risk/High Reward Name - Seeking Alpha
Why Capricor Therapeutics (CAPR) Is Down 15.8% After Phase 3 Win And $1.5 Billion Deal - simplywall.st
Here's Why This Biotechnology Skyrocketed by 439% in December - Yahoo Finance
How interest rate cuts could boost Capricor Therapeutics Inc. stockMarket Trend Summary & Real-Time Volume Spike Alerts - ulpravda.ru
Investment Recap: How interest rate cuts could boost Capricor Therapeutics Inc. stockJuly 2025 Reactions & Weekly Top Stock Performers List - ulpravda.ru
Can Capricor Therapeutics Inc. stock weather global recession2025 Geopolitical Influence & Technical Pattern Recognition Alerts - ulpravda.ru
Capricor Therapeutics, Inc.Common Stock (NQ: CAPR - FinancialContent
FDA Decisions to Look For in 1H 2026 - CGTLive®
(CAPR) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Finanzdaten der Capricor Therapeutics Inc-Aktie (CAPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Capricor Therapeutics Inc-Aktie (CAPR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Marban Linda | CHIEF EXECUTIVE OFFICER |
Mar 03 '25 |
Option Exercise |
1.39 |
25,000 |
34,750 |
223,604 |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Mar 03 '25 |
Option Exercise |
1.39 |
2,500 |
3,475 |
8,223 |
| Litvack Frank | Director |
Mar 03 '25 |
Option Exercise |
1.39 |
25,000 |
34,750 |
132,382 |
| DUNBAR GEORGE W JR | Director |
Mar 03 '25 |
Option Exercise |
1.39 |
750 |
1,042 |
11,306 |
| COLLIER EARL M JR | Director |
Feb 27 '25 |
Option Exercise |
1.39 |
750 |
1,042 |
57,606 |
1.24%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):